Home › Bladder Cancer › Indiana
Bladder Cancer clinical trials in Indiana
14 studies for Bladder Cancer are looking for participants at sites in Indiana.
Cities in Indiana
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07566156A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- IU Simon Cancer Center, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06465069Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- Urology of Indiana - Carmel, Carmel
- Urology of Indiana, LLC (US Urology Partners), Greenwood
- First Urology, PSC, Jeffersonville
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06567743Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Reid Health, Richmond
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Indiana University (IU) Melvin and Bren Simon Cancer Center, Indianapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05614739LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Urology of Indiana, Greenwood
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT04752722Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- IU Health West Hospital, Avon
- IU Health North Hospital, Carmel
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07000084A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- UChicago Medicine - Northwest Indiana, Crown Point
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
- Community Health Network, Inc, Indianapolis
- and 3 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
- Urologic Specialists of Northwest Indiana, Merrillville
Recruiting
Ages 18 to 88 · All sexes · Updated Jul 2, 2026 · NCT06394869Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
- Indiana University School of Medicine, Indianapolis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 23, 2026 · NCT05982561cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881Blue Light Cystoscopy With Cysview® Registry
- Indiana University School of Medicine, Indianapolis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT02660645From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.